Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (181-190 of 361) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyCharles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate CancerThomas A Hope, Rahul Aggarwal, Bryant Chee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary-Ellen Taplin, Barur Rajeshkumar, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerMatthew D Galsky, Eric J Small, William K Oh, et al.
Prostate International|January 11, 2021
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 studyHiroji Uemura, Takefumi Satoh, Hideyasu Tsumura, et al.
European Urology Focus|July 21, 2017
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream TeamRahul Aggarwal, Tomasz M Beer, Martin Gleave, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2006
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerEric J Small, Michael A Carducci, James M Burke, et al.
Cancer|April 7, 2005
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinomaJonathan E Rosenberg, Hans von der Maase, John D Seigne, et al.
Cancer|November 2, 2006
Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B studyAlice B Kornblith, Jeannette M Dowell, James E Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Pageof 37

Showing results (181-190 of 361) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyCharles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate CancerThomas A Hope, Rahul Aggarwal, Bryant Chee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary-Ellen Taplin, Barur Rajeshkumar, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancerMatthew D Galsky, Eric J Small, William K Oh, et al.
Prostate International|January 11, 2021
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 studyHiroji Uemura, Takefumi Satoh, Hideyasu Tsumura, et al.
European Urology Focus|July 21, 2017
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream TeamRahul Aggarwal, Tomasz M Beer, Martin Gleave, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2006
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancerEric J Small, Michael A Carducci, James M Burke, et al.
Cancer|April 7, 2005
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinomaJonathan E Rosenberg, Hans von der Maase, John D Seigne, et al.
Cancer|November 2, 2006
Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B studyAlice B Kornblith, Jeannette M Dowell, James E Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Pageof 37